Safety and efficacy of generic nab-paclitaxel-based therapy in Chinese patients with malignant tumors in a real-world setting: a multicenter prospective observational study.

ABSTRACT:

Objective

This study aimed to assess the safety and efficacy of generic nab-paclitaxel in the Chinese population in a real-world setting.

Methods

This prospective, multicenter, observational study enrolled patients with malignancies who received any generic nab-paclitaxel-based regimens in China. The primary endpoint was safety, and secondary endpoint was objective response rate (ORR). Logistic regression was used to explore risk factors for adverse events (AEs) of special interest (AESIs).

Results

Between September 2019 and April 2023, 1168 patients were enrolled and evaluated for safety, and 602 were assessed for tumor response. Of 1168 patients, 169 (14.5%) received generic nab-paclitaxel monotherapy, and 999 (85.5%) received generic nab-paclitaxel-based combinatio

SUBMITTER: He F 

PROVIDER: S-EPMC11599493 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature